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ABSTRACT
Objectives Preoperative anaemia is associated with 
increased risks of postoperative complications, blood 
transfusion and mortality. This meta- analysis aims 
to review the best available evidence on the clinical 
effectiveness of preoperative iron in anaemic patients 
undergoing elective total hip (THR) or total knee 
replacement (TKR).
Design Electronic databases and handsearching were 
used to identify randomised and non- randomised studies 
of interventions (NRSI) reporting perioperative blood 
transfusion rates for anaemic participants receiving 
iron before elective THR or TKR. Searches of CENTRAL, 
MEDLINE, Embase, PubMed and other databases were 
conducted on 17 April 2019 and updated on 15 July 2020. 
Two investigators independently reviewed studies for 
eligibility and evaluated risk of bias using the Cochrane 
risk of bias tool for randomised controlled trials (RCTs) 
and a modi"ed Newcastle- Ottawa scale for NRSIs. Data 
extraction was performed by ABS and checked by AB. 
Meta- analysis used the Mantel- Haenszel method and 
random- effects models.
Results 807 records were identi"ed: 12 studies met 
the inclusion criteria, of which 10 were eligible for meta- 
analyses (one RCT and nine NRSIs). Five of the NRSIs 
were of high- quality while there were some concerns 
of bias in the RCT. Meta- analysis of 10 studies (n=2178 
participants) showed a 39% reduction in risk of receiving 
a perioperative blood transfusion with iron compared with 
no iron (risk ratio 0.61, 95% CI 0.50 to 0.73, p<0.001, 
I2=0%). There was a signi"cant reduction in the number 
of red blood cell units transfused with iron compared with 
no iron (mean difference −0.37units, 95% CI −0.47 to 
-0.27, p<0.001, I2=40%); six studies (n=1496). Length of 
stay was signi"cantly reduced with iron, by an average of 
2.08 days (95% CI −2.64 to −1.51, p<0.001, I2=40%); "ve 
studies (n=1140).
Conclusions Preoperative iron in anaemic, elective 
THR or TKR patients, signi"cantly reduces the number 
of patients and number of units transfused and length 
of stay. However, high- quality, randomised trials are 
lacking.
PROSPERO registration number CRD42019129035.
INTRODUCTION
Over 175 000 primary, elective total hip 
(THR) or total knee replacements (TKR) 
were performed in the UK in 2018–2019.1 
Up to one in three of those patients would 
be expected to have preoperative anaemia, 
the majority of which is caused by absolute 
or functional iron deficiency in this popula-
tion.2–6 Preoperative anaemia is an indepen-
dent risk factor for increased perioperative 
complications, mortality, allogenic red blood 
cell (RBC) transfusion and longer length of 
hospital stay (LoS).7 RBC transfusion itself 
is also independently associated with poorer 
postoperative outcomes and longer LoS.7 
Elective orthopaedic surgery is described as 
one of the most appropriate fields for imple-
mentation of preoperative anaemia optimisa-
tion.8 Erythropoietin (EPO) is one option for 
optimising preoperative anaemia; however, 
there are concerns that routine use is not cost 
Strengths and limitations of this study
 ﾓ This review has a pragmatic approach to inclusion 
criteria and is focused on one particular type of 
elective surgery, which is considered as one of the 
most appropriate "elds for preoperative anaemia 
optimisation.
 ﾓ Comprehensive database and handsearching tech-
niques have been employed to identify the best 
available evidence on this topic, and rigorous sensi-
tivity analyses of results have been undertaken.
 ﾓ The results of this review are limited by the quali-
ty of the included studies. A lack of well- conducted 
randomised controlled trials means insuf"cient ev-
idence is available to reliably inform future clinical 
practice or guideline development.
 ﾓ The quality of reporting in the included studies, par-
ticularly around the underlying cause of anaemia, 
other coexisting patient blood management strate-
gies and patient adherence also limit the results of 
this review.
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effective.9 10 The National Institute for Health and Care 
Excellence in the UK and multiple international guide-
lines recommend iron treatment(s) be used to optimise 
anaemia caused by iron deficiency, in the preoperative 
period.10–13 However, a recent report from the Royal 
College of Anaesthetists found 70% of anaemic patients 
received no treatment for anaemia in the 3 months before 
surgery.14
There is mounting evidence that multimodal patient 
blood management (PBM) programmes can be effec-
tive at improving postoperative outcomes and reducing 
perioperative blood transfusions and costs.15 16 A PBM 
programme typically consists of three ‘pillars’; (1) opti-
mising red cell mass, (2) reducing blood loss and (3) 
harnessing and optimising physiological reserve of 
anaemia.17 While some elements of PBM have a strong 
evidence base in hip or knee replacement, such as the 
use of tranexamic acid (TXA)18 and reduced transfu-
sion thresholds,19 the evidence for preoperative anaemia 
optimisation with iron is less robust.13 This coupled with 
organisational barriers and misconceptions around treat-
ment options may be contributing to poor uptake.20 21
The question addressed by this review is, does preoper-
ative iron improve postoperative blood transfusion rates 
and outcomes, in patients with preoperative anaemia 
undergoing primary, elective THR or TKR? Although 
the majority of preoperative anaemia in this population 
is likely to be due to iron deficiency, iron alone will not 
address preoperative anaemia for all patients and guide-
lines recommend the underlying cause of anaemia should 
be ascertained before starting treatment.2 3 10 13 In recog-
nition that iron will not be appropriate for all patients 
and in an attempt to make the results more generalis-
able, we included studies using another intervention to 
treat preoperative anaemia, such as EPO, for up to 20% 
of participants. This figure is based on a multicentre 
cohort study showing approximately 85% of preoperative 
anaemia in elective surgical patients is due to iron defi-
ciency (functional or absolute) or low iron stores, and 
may respond to iron.2
METHODS
CENTRAL, MEDLINE, Embase, PubMed, ISI Web of 
Science, Transfusion Library,  ClinicalTrials. gov, ICTRP, 
ISRCTN and ProQuest databases were searched using 
the search strategies in online supplemental appendix 
1A. An example of search terms used include (“iron” 
OR “iron compounds” OR “ferrous compounds” OR 
“ferric compounds”) AND (“anemia” OR “anemia, iron 
deficiency”) AND (“preoperative period” OR “preoper-
ative care” OR perioperative period” OR “preoperative 
care”) AND (“orthopedics” OR “hip” OR “hip joint OR 
“hip prosthesis” OR “arthroplasty, replacement, hip” OR 
“knee” OR “knee joint” OR “knee prosthesis” OR “arthro-
plasty, replacement, knee”). Searches were performed 
on 17 April 2019 with no date or language restrictions 
applied and were updated on 15 July 2020.
The reference lists of the most recent clinical guide-
lines for preoperative anaemia from Europe, Australia 
and the USA, existing systematic reviews on a similar 
topic and expert opinion pieces were scanned for addi-
tional studies. Abstracts from relevant conferences from 
January 2009 to April 2019 were hand searched, and field 
experts and relevant pharmaceutical companies were 
contacted to obtain any unpublished trials. Where trial 
protocols were found by the searches we also searched 
for any results papers. Forward and backward reference 
searching of the included studies was performed. Search 
results were collated in Covidence systematic reviews soft-
ware (Veritas Health Innovation, Melbourne, Australia).
This review includes randomised controlled trials 
(RCTs) and non- randomised studies of interventions 
(NRSI) with a control group that report perioperative 
blood transfusion rates for adult, anaemic participants 
who received iron treatment (enteral or parenteral) 
before undergoing elective THR or TKR. Anaemia is 
traditionally defined as haemoglobin (Hb) values less 
than 130 g/L for males and 120 g/L for non- pregnant 
females.22 However, in recognition of views that a non- 
gender based cut- off of 130 g/L for males and females 
is more appropriate,12 we accepted any clear definition 
of anaemia by the study investigators. Eligible compar-
ators were another form of iron treatment, placebo, no 
anaemia treatment or standard care.
The primary outcome was perioperative blood trans-
fusion rate. Other outcomes of interest were quantity 
of blood transfused (units), change in Hb or ferritin 
concentration, morbidity including infection and other 
adverse events, mortality, LoS, critical care admission 
rate, readmission rate, compliance with iron and any vali-
dated quality of life (QoL) measure. Studies that include 
participants undergoing THR or TKR following trauma 
or where the intervention included autologous transfu-
sion methods were excluded.
Following deduplication, two authors (ABS and AB) 
independently reviewed titles and abstracts to assess study 
eligibility against the predefined criteria. Full manu-
scripts of any potentially eligible records were obtained 
and screened using the same method. Multiple accounts 
of the same study were excluded. A record of excluded 
studies is provided in online supplemental appendix 1B.
One author (ABS) extracted data from each study using 
a prepiloted data extraction form. Data were checked 
by a second author (AB). Disagreements on inclusion 
of studies and data extractions were discussed and a 
consensus reached. Where information was unclear, 
attempts were made to contact study authors for further 
details. Where available as a subgroup, only data for 
participants receiving iron were extracted.
The two reviewers (ABS and AB) independently 
assessed the risk of bias and quality of studies using 
the Cochrane Risk of Bias (RoB2) tool for randomised 
studies and the Newcastle- Ottawa scale (NOS) for 
NRSIs.23 24 Again, disagreements were discussed, and 
a consensus reached. A modified version of the NOS, 
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excluding fields of ‘demonstration that outcome 
of interest was not present at start of study’ and ‘was 
follow- up long enough’, was used as these were not 
applicable to this review. The maximum score using our 
modified NOS is 7 stars. To reduce variability in applying 
the NOS between authors, detailed criteria were devel-
oped specific to this review (see online supplemental 
appendix 1C).
Standard criteria for defining high- quality or low- 
quality studies using this modified NOS do not exist. For 
this review, studies scoring ≤4 stars or at high risk of bias 
on RoB2 were defined as being of low quality. This is 
based on a previous review which used a similarly modi-
fied NOS.25
We planned to perform meta- analysis of postopera-
tive outcomes and where sufficient data were available, 
subgroup analyses comparing types of iron, types of 
surgery and the use of concurrent treatments. However, 
sufficient data were only available to perform subgroup 
analysis for different types of iron. To control for the one 
study that used EPO in two participants, it was excluded 
as part of the sensitivity analyses. In addition, we under-
took an exploratory analysis of correlation between pre- 
iron Hb and type of iron treatment on the change in Hb 
concentration following iron. We have also conducted 
sensitivity analyses to assess the robustness of our results.
Meta- analysis was undertaken using Review Manager 
V.5.3 (The Cochrane Collaboration, Oxford, UK). The 
Mantel- Haenszel method was employed using risk ratios 
(RR). A random- effects model was used due to expected 
methodological heterogeneity among studies in relation 
to iron drug, dose and timing, definitions of anaemia 
and transfusion thresholds. Mean differences (MD) were 
calculated where appropriate depending on homoge-
neity of units of reporting (ie, RBC units). The I2 statistic 
was used to assess heterogeneity. In keeping with previous 
Cochrane reviews, moderate and substantial heteroge-
neity were defined as an I2 of more than 50% or 85%, 
respectively.19 26
Differences were seen in how studies reported data 
on the number of RBC units transfused. Some studies 
reported an average only for the subpopulation who 
received a transfusion and others an average for the 
entire cohort undergoing surgery. In studies reporting 
only for those who had a transfusion, it is known the 
rest of that cohort population, those not transfused, all 
received zero RBC units. In order to allow meaningful 
pooling of results, methods of combining means were 
used to convert these into averages for the entire cohort 
undergoing surgery (online supplemental appendix 1D).
This review includes studies with any clear definition 
of anaemia, this resulted in the inclusion of two studies 
in which participants have a presenting Hb level (130–
140 g/L) that by traditional WHO definitions would be 
considered non- anaemic.27–30 It is also thought intrave-
nous iron leads to a greater Hb increase than oral iron.30 
Subgroup and meta- regression analyses were performed 
to investigate these associations further.
When pooling data on pre- iron and post- iron Hb 
concentrations, correlation is expected as these data are 
from the same participants. As such, a correlation coeffi-
cient (CC) is required to accurately calculate a MD and 
variance. As no published CC were identified, these were 
calculated for oral (0.56) and intravenous (0.70) iron from 
a local dataset, made available to reviewers.31 Comprehen-
sive Meta- analysis (V.2, Biostat, USA) was used to calculate 
the MD, SD and SE for each study reporting pre- iron and 
post- iron Hb data and meta- regression was performed in 
Stata (V.15.1 StataCorp) using the ‘metareg’ command.32
In accordance with recommendations from the 
Cochrane Collaboration, as 10 studies were included in 
the meta- analysis of the primary outcome a funnel plot 
was generated and visually inspected to assess for publica-
tion bias.26 For all statistical tests a p<0.05 was considered 
statistically significant. Sensitivity analysis of the pooled 
results was performed excluding studies where the under-
lying cause of anaemia was not specifically reported as 
being iron deficiency; low- quality studies; those with any 
imputed data; those using a concurrent anaemia treat-
ment (ie, EPO); and those with an average presenting Hb 
>130 g/L.
Where studies report outcomes separately for oral 
and IV iron, outcomes were analysed separately for the 
effects on Hb concentration, but the oral and intrave-
nous groups data were combined for inclusion in meta- 
analysis on postoperative outcomes (online supplemental 
appendix 1E), using methods recommended in the 
Cochrane handbook.26
Patient and public involvement
There was no patient or public involvement in this 
meta- analysis.
RESULTS
Literature search
Following deduplication 807 records were identified 
from the search strategy (figure 1). Based on screening 
of titles and abstracts 138 records underwent full- text 
review. Of these, nine met the inclusion criteria. One 
additional study was identified by handsearching for the 
final publication related to a trial protocol found. This 
study was identified in a non- PubMed indexed peer- 
reviewed journal, which is why it was not identified by 
our database searches. Both authors agreed this study 
met the inclusion criteria for this review. Forward citation 
searches of the ten eligible studies identified one further 
study for inclusion, in the KoreaMed database. A search 
of this database identified no other relevant studies. Elec-
tronic database search updates in July 2020 identified 175 
studies. Following deduplication and screening, one addi-
tional study was eligible for inclusion in this review.33
A total of 12 identified studies were eligible for this 
review.28 29 31 33–41
Study characteristics and quality
The characteristics of the 12 included studies are given 
in tables 1–3 and figure 2. Three studies tested the effects 
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of oral iron salts, two of oral sucrosomial iron, four of 
intravenous iron and three of a combined approach of 
oral and/or intravenous iron. The average timing of 
iron treatment before surgery ranged from 2 to 60 days. 
Intravenous iron was typically given in 1–2 sessions within 
4 weeks of surgery, while oral iron was typically given for 
4 weeks, a month or more before surgery. Comparators 
were no preoperative iron (standard care), oral iron 
or intravenous iron. Eight studies report routine use 
of restrictive transfusion triggers across all groups, two 
report using non- restrictive triggers40 41 and two did not 
report this.34 35 Four studies report the ‘routine use’ of 
TXA28 31 33 38; however, only one of these studies formally 
assess this.33 Three studies report that cell salvage was not 
routinely used.28 29 38 Two studies were excluded from the 
meta- analysis on postoperative outcomes due to hetero-
geneity in their control groups. Ten studies included an 
anaemic control group that received no iron, while in one 
study two types of IV iron were compared34 and another 
only included a non- anaemic control group.41
Of the 10 studies included in the meta- analysis of post-
operative outcomes, nine were comparative cohort studies 
and one a RCT. Nine were full peer- reviewed publications 
and one a conference abstract, which was later excluded 
in the sensitivity analysis due to poor quality.35 Two studies 
were in non- English language and required translation by 
a third (PS, French) and fourth (IHL, Korean) reviewer 
familiar with systematic review techniques and fluent in 
the relevant language. For these studies data extraction 
and quality assessment was performed by the translating 
reviewer under the guidance of ABS. Detailed guidance of 
the Newcastle- Ottawa scoring criteria used for this review 
can be found in table 4. Of the 10 studies, four were of 
low quality.33 35 39 40 Visual inspection of the funnel plot 
Figure 1 Flow chart of study selection.
 o
n
 N
o
v
e
m
b
e
r 3
, 2
0
2
0
 b
y
 g
u
e
s
t. P
ro
te
c
te
d
 b
y
 c
o
p
y
rig
h
t.
h
ttp
://b
m
jo
p
e
n
.b
m
j.c
o
m
/
B
M
J
 O
p
e
n
: firs
t p
u
b
lis
h
e
d
 a
s
 1
0
.1
1
3
6
/b
m
jo
p
e
n
-2
0
1
9
-0
3
6
5
9
2
 o
n
 3
1
 O
c
to
b
e
r 2
0
2
0
. D
o
w
n
lo
a
d
e
d
 fro
m
 
5
S
crim
sh
ire
 A
B
, et al. B
M
J O
p
en
 2
0
2
0
;1
0
:e0
3
6
5
9
2
. d
oi:1
0
.1
1
3
6
/b
m
jop
en
-2
0
1
9
-0
3
6
5
9
2
O
p
e
n
 a
c
c
e
s
s
Table 1 Included study characteristics
Author Trial design Procedures
De!nition of 
anaemia (g/L)*
Intervention Comparator
Concurrent 
treatment Transfusion threshold*
Drug, route and 
dose
Timing of 
treatment 
before surgery Duration
Drug, route and 
dose
Timing of 
treatment 
before 
surgery Duration
Andrews, 199741 Randomised 
non- anaemics 
to iron or not. 
Non- randomised 
group of 
anaemics all 
given iron (quasi- 
experimental)
Elective primary 
THR and TKR
Hb <120
No mention of 
underlying cause/
iron de!ciency
Oral ferrous 
sulphate 200 mg 
b.d.
At least 4 weeks 4 weeks Participants with Hb >12 randomised to oral 
iron (same dose and duration) or standard 
care (no iron pre- op)
All participants 
had postoperative 
oral iron until 
discharge
Hb <100 g/L
Bae, 201037 Retrospective 
cohort study
Elective TKR Hb <120
No mention of 
underlying cause/
iron de!ciency
IV ferric 
hydroxide 
sucrose complex 
200 mg
(+100 mg, if Hb 
<12 the day 
before operation)
2 days 
preoperative
Single dose Standard care (no iron preoperative) None given Hb <80 g/L
Bisbe, 2011
(letter)34
Retrospective 
cohort study
Elective 
lower limb 
arthroplasty
Hb <120 F
Hb <130 M and 
‘iron de!ciency’
IV FCM
Total dose†
Mean 1000 mg 
SD 490
Not reported Sessions Mean 
2 SD 1
IV Iron Sucrose Total 
dose†
Mean 830 mg SD 
270
Not 
reported
Sessions 
Mean 4 
SD 4
None given –
Costanzo, 2017 
(abstract)35
Prospective 
cohort study
Elective Hip 
arthroplasty
Not reported
(Max Hb of 
included 
participants 125)
Oral Sucrosomial 
iron one tablet od
1 month 1 month Standard care None given –
Gonzalez- Porras, 
200929
Prospective 
cohort study 
(matched)
Elective primary 
THR or TKR
130≤Hb < 140
Ferritin <250 μg/
L=oral iron
<50 μg/L or oral 
intolerant=IV iron
Oral ferrous 
sulphate 315 mg 
per day until 
surgery
Median 31 days
Range 6–151
Median 31 days
Range 6–151
Standard care None given Hb <70 g/L if previously 
healthy
Hb <80 with 
uncontrolled 
haemorrhage or poor 
tolerance of anaemia
Hb <90 if cardiac or 
respiratory failure
IV iron sucrose 
200 mg per week 
until surgery
Median 29 days
Range 7–91
Minimum 2 
weeks
Heschl, 201838 Retrospective 
cohort study
Elective 
hip or knee 
arthroplasty
Hb <120 F
Hb <130 M
Ferritin <100 μg/L, 
TSAT <20%
IV FCM
Mean 1244 mg 
SD 877 mg
Mean 11.2 days 
SD 8.9
– Standard care None given‡ Hb <70 g/L or <80 
in participants with 
cardiopulmonary 
restrictions
Khalafallah, 2012
(RCT)36
Randomised IV 
vs Oral iron
Plus a third 
non- randomised 
group used as a 
control
Elective THR or 
TKR
<120 F
<140 M
Excluded if <90
Ferritin
<100 μg/L
IV iron 
polymaltose Total 
dose†
Median 22 days 
Range 14–38
Single dose 1 - Oral iron 
sulphate 325 mg o.d. 
(105 mg elemental 
iron) for 3–4 weeks
Median 
22 days 
Range 
14–38
Median 
22 days 
Range 
14–38
None given Hb <80 g/L
2 - Standard care 
(non- randomised
Not 
applicable
Not 
applicable
None given
Myers, 200440 Prospective 
cohort study
Elective primary 
THR
Hb <115 F
Hb <125 M
‘iron de!cient 
anaemia’ 
subgroup
Oral iron dose not 
reported
– – Standard care None given Haematocrit <30%
(approx. equivalent to 
Hb <100 g/L)§
Continued
 on November 3, 2020 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2019-036592 on 31 October 2020. Downloaded from 
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Author Trial design Procedures
De!nition of 
anaemia (g/L)*
Intervention Comparator
Concurrent 
treatment Transfusion threshold*
Drug, route and 
dose
Timing of 
treatment 
before surgery Duration
Drug, route and 
dose
Timing of 
treatment 
before 
surgery Duration
Pinilla- Gracia, 
202033
Retrospective 
cohort
Elective primary 
THR
Hb <130
No mention of 
underlying cause/
iron de!ciency
IV FCM
1000 mg
4 weeks Single dose Standard care Both groups 
received three 
doses IV iron 
sucrose, 200 mg, 
within 48 hours 
of admission, 
parenteral vitamin 
B
12
 (1 mg) and 
oral folic acid 
(5 mg/day) during 
hospitalisation
Symptomatic, Hb 
<80 g/L or Hb <100 g/L 
if history of IHD or PVD.
Pujol- Nicolas, 
201731
Prospective 
cohort study
Elective primary 
THR or TKR
Hb <120 F
Hb <130 M
Ferritin 12-100 
μg/L
Oral ferrous 
sulphate 200 mg 
three times a day
IV FCM 500 mg if 
<50 kg 1000 mg 
if >50 kg if poor 
renal function or 
poor response to 
oral iron
Median 59.5 
days¶
Oral 28 days
IV single dose
Standard care None given <80 g/L or 80–100 g/L if 
symptomatic
Razurel, 201439 Prospective 
cohort study
Elective primary 
THR or TKR
Hb <120 F
Hb <130 M
‘iron de!ciency’
Oral ferrous 
sulphate
160 mg OD
Mean 9.0 days
SD 0.8
– Standard care None given Hb <70 g/L
Considered if 
80<Hb<90 and 
cardiovascular disease
90<Hb<100 and 
symptomatic anaemia 
or heart failure
Scardino, 201928 Retrospective 
cohort study
Elective primary 
hip arthroplasty
120<Hb<135 F
130<Hb<140 M
Ferritin <100 μg/L 
or ferritin 
>100 μg/L but 
CRP >3 mg/L and 
TSAT <20%
Oral Sucrosomial 
iron 30 mg od
3–4 weeks 3–4 weeks Standard care 2% (n=2) 
participants in 
intervention group 
also had EPO
Hb <70 g/L or <90 with 
tachycardia
Standard care=no preoperative anaemia treatment/iron.
*Hb converted to g/L for all studies.
†Total dose calculated based on Ganzoni formula of iron de!cit.65
‡Data extracted for 25% treated with iron only, EPO used in 75% of participants in trial.
§Calculation based on haemoglobin (g/dL) approximately equals haematocrit/3.66
¶Time from clinic to surgery, not strictly timing of treatment.
bd, twice daily; EPO, erythropoietin; FCM, ferric carboxymaltose; Hb, haemoglobin; IHD, ischaemic heart disease; IV, Intravenous; od, once daily; PO, oral; PVD, peripheral vascular disease; RCT, randomised controlled trial; tds, three time daily; 
THR, total hip replacement; TKR, total knee replacement.
Table 1 Continued
 on November 3, 2020 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2019-036592 on 31 October 2020. Downloaded from 
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Table 2 Population characteristics and outcomes
Author Group (n)
Completed 
treatment Age (years) Sex
THR:TKR 
split
Presenting Hb 
(g/L) before iron)
Hb after iron but 
before surgery 
(g/L)
Postoperative 
hb (g/L)
No of 
participants 
transfused
No of units 
transfused
Length of 
stay (days)
Andrews, 199741 Anaemic +iron 
(n=18)
n=16 Mean 68 11 F
5 M
9 THR
7 TKR
Mean 108 
Range 97–118 
Estimated SD* 
5.25
Mean 119
Estimated SD 
5.25
n=12
Day one to Day 
5.6=drop of 
16 g/L
– Mean 2.8†
Repeat 
transfusions 4 
of 16
–
No anaemia +iron 
(n=41)
n=35 Mean 67 15 F
20 M
19 THR
16 TKR
Mean 138 “No signi!cant 
increase”
n=25
Day one to Day 
5.3=drop of 4 
95% CI±2.8
– Mean 1.7†
Repeat 
transfusions 0 
of 35
–
No anaemia no iron 
(n=40)
Not applicable Mean 67 17 F
23 M
15 THR
25 TKR
Mean 140 Not applicable n=29
Day one to Day 
5.3=drop of 13 
95% CI±2.9
– Mean 1.8†
Repeat 
transfusions 3 
of 40
–
Bae, 201037 IV iron n=30 n=30 Mean
65.3
30 F 12 unilateral 
TKR 18 
bilateral TKR
– 122 48 hours 94
7 days 104
n=17 Mean 1.3‡
Estimated SD: 
0.733
17.5 
Estimated 
SD: 2.898
Control n=30 Not applicable Mean
68.2
28 F
2 M
15 unilateral 
TKR 15 
bilateral TKR
127 Not applicable 48 hours 87
7 days 102
n=22 Mean 1.7‡
Estimated SD: 
0.515
20.2 
Estimated 
SD: 4.202
Bisbe, 201134 IV Iron Sucrose 
(n=21)
n=21 Mean 72 
range 53–88
17 F
4 M
– Mean 107 SD 11 Mean 126 SD 10 – n=6
(29%)
– –
IV FCM (n=42) n=42 Mean 68 
Range 46–82
37 F
5 M
– Mean 109 SD 17 Mean 128 SD 9 – n=6
(14%)
– –
Costanzo, 
201735
Oral iron (n=10) n=10 65–70 5 F
5 M
10 THR Mean 105 SD 5 Mean 115 SD 5 “Post- op”
Mean 85 SD 5
n=0 – –
Control (n=10) Not applicable 65–70 5 F
5 M
10 THR Mean 120 SD 5 Not applicable “Post- op”
Mean 75 SD 5
n=4
(40%)
– –
Gonzalez- 
Porras, 200929
IV iron
(n=49)
n=49 – – – Mean 133 SD 2 Mean 143 SD 2 At discharge
Mean 103 SD 8
n=10
(20.4%)
Total units=18
Mean 0.37† 
SD 0.52
–
Oral iron (n=145) n=145 – – – Mean 141 SD 9 Mean 143 SD 8 At discharge
Mean 107 SD 1
n=29
(20%)
Total no of 
units=46
Mean 0.31† 
SD 0.47
–
Control (n=305) Not applicable Mean 68.8 
SD 9.9
181 F
124 M
163 THR
142 TKR
Mean 149 SD 4 Not applicable At discharge
Mean 111 SD 8
n=96
(31.5%)
Total units=233
Mean 0.77† 
SD 1.36
–
Heschl, 201838 IV iron (n=83) n=83 (100%) – – – – – – Assumed 12% 
from paper 
n=10
Mean 0.36† 
SD 0.75
–
Control (n=331) Not applicable – – – – – – n=80
(24%)
Mean 0.5† SD 
1.3
–
Continued
 on November 3, 2020 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2019-036592 on 31 October 2020. Downloaded from 
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Author Group (n)
Completed 
treatment Age (years) Sex
THR:TKR 
split
Presenting Hb 
(g/L) before iron)
Hb after iron but 
before surgery 
(g/L)
Postoperative 
hb (g/L)
No of 
participants 
transfused
No of units 
transfused
Length of 
stay (days)
Khalafallah, 
201236
IV Iron (n=22) n=16 Median 68 19 F
14 M
17 THR
16 TKR
Median 110 
Range 90–130
Estimates*: Mean 
110, SD 10
Mean 128.47 SD 
11.05
48 hours: Mean 
92.65 SD 12.57
6 weeks: 120.88 
SD 13.8
n=4
(25%)
Mean 1.50, SD 
0.58‡
Mean 6.24 
SD 2.51
Oral Iron (n=22) n=17 Mean 118.44 SD 
9.23
48 hours: Mean 
87.75 SD 11.73
6 weeks: Mean 
108.94 SD 11.15
n=5
(29%)
Mean 2.22, SD 
0.83‡
Mean 8.00 
SD 3.62
Control (n=18) Not applicable “Age and sex matched” 11 THR
7 TKR
Mean 116 SD 
8.46 Range 
92–135
Not applicable 48 hours: Mean 
87.91 SD 12.72
6 weeks – not 
available
n=6
(33%)
Mean 2.44, SD 
0.73‡
Mean 7.72 
SD 4.18
Myers, 200440 Oral iron (n=4) n=4 – – 4 THR – – – n=2 (50%) – –
Control (n=17) Not applicable – – 17 THR – – – n=15 (88%) – –
Pinilla- Gracia, 
202033
IV iron
(n=9)
n=9 – – 9 THR Mean 125 SD 6 Mean 132
SD 7
– n=1 (11%) – –
No iron
(n=75)
Not applicable Mean 71
SD 12
60 F
15 M
75 THR Mean 122 SD 7 Not applicable Day one post- op
Mean 95 SD 12
n=18 (24%) 33 units Median 6
IQR 5–7
Pujol- Nicolas, 
201731
Intervention 
(n=196)
Oral iron=120
IV iron=12
Referred for 
investigation§=64
– – – – – – n=22 (11.28%) Median: 2‡ 
IQR 2–2, 
Range 1–6
Estimated¶ 
Mean 2.426 
SD 1.216
Mean 4.9 
SD 5.284
Range 0–42
Control (n=265) Not applicable – – – – – – n=65 (24.52%) Median: 2‡ 
IQR 2–2.75, 
Range 1–6
Estimated¶ 
Mean 2.577 
SD 1.162
Mean 6
SD 7.627
Range 1–93
Razurel, 201439 Oral iron
(n=30)
n=30 70.9 18 F
12 M
13 THR
17 TKR
– Mean 133 SD 2 Immediate post- 
op:
Mean 117 SD 2
n=6
(20%)
– Mean 8.3 
SD 0.3
Control
(n=327)
Not applicable 71.6 217 F
110 M
205 THR
122 TKR
Mean 129 SD 2 Not applicable Immediate post- 
op:
Mean 111 SD 1
n=95
(29%)
Mean 2.3‡±SD 
0.3
Mean 10.6 
SD 0.8
Table 2 Continued
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for the primary outcome, perioperative blood transfusion 
rate, (figure 3) suggests an asymmetrical appearance, 
with a possible absence of published, smaller studies that 
show no statistically significant effect. This suggests there 
may be publication bias towards the positive effects of 
iron, with the risk that the pooled estimate may be an 
overestimation of the true intervention effect; however, 
other explanations cannot be ruled out and the number 
of studies in the plot just meets the minimum required.26
Risk of transfusion
Eight studies reported the number of participants receiving 
perioperative allogenic RBC transfusion with iron treat-
ment compared with no iron treatment.29 31 33 35–37 39 40 
This outcome was estimated from related data in a further 
two studies.28 38 In one of these studies the intervention 
includes iron±EPO, here subgroup data for participants 
receiving only iron has been extracted.38 This paper states 
that there was no significant difference in the transfusion 
rate between participants who received iron alone or iron 
and EPO, so we have estimated the number of partic-
ipants transfused in the iron only subgroup based on 
the proportion reported (12%). In the other study only 
the number of RBC units transfused has been reported 
(n=7).28 In order to reduce the risk of inflating the effect 
size of iron, we have assumed these units have been given 
to the smallest plausible number of participants (n=1).
Ten studies (n=2178 participants) were pooled 
(figure 4). The transfusion rate in the iron groups 
combined was 15.1% (106/700) compared with 27.2% in 
the control group (402/1478). Treating anaemic partici-
pants with iron before THR or TKR significantly reduces 
the risk of receiving a perioperative blood transfusion 
by 39% (RR 0.61, 95% CI 0.50 to 0.73, p<0.0001). There 
was no evidence of heterogeneity (I2=0%), there were no 
significant subgroup differences (p=0.35).
Sensitivity analyses excluding studies where the under-
lying cause of anaemia was not reported as iron defi-
ciency,33 35 37 low- quality studies,33 35 39 40 studies with any 
estimated values,28 38 studies using concurrent EPO,28 
studies with a presenting Hb >130 g/L,28 29 or all of the 
above, had no discernible effect on the effect size esti-
mate (see online supplemental appendix 1F).
Number of RBC units transfused
Five studies (n=1496 participants) report the number 
of RBC units transfused,29 31 36–38 three of these required 
conversion to population level statistics.31 36 37
There was an average reduction of 0.37 RBC units 
(95% CI −0.47 to −0.27, p<0.001) transfused per anaemic 
patient undergoing elective THR or TKR in the preopera-
tive iron group compared with control (figure 5). Hetero-
geneity was low (I2=40%) and there were no significant 
subgroup differences (p=0.06).
None of these studies were of low quality or used 
a concurrent treatment, all studies report the cause 
of anaemia as being iron deficiency. Sensitivity anal-
yses excluding studies where the variance had been A
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Table 3 Quality assessment of included non- randomised studies of interventions
Author
Selection Comparability* Outcome
Total
(max. 7⋆)
Representativeness 
of the exposed 
cohort (⋆)
Selection of 
non- exposed 
cohort (⋆)
Ascertainment of 
exposure (⋆) (⋆⋆) Assessment (⋆)
Adequacy of 
follow- up of 
cohorts (⋆)
Andrews, 199741 幕 幕 幕     幕幕幕 (3)
Bae,201037 幕 幕 幕 - 幕 幕 幕 幕幕幕幕幕幕 (6)
Bisbe, (Letter) 201134   幕 幕 幕幕 (2)
Costanzo, (Ab) 201735           0
Gonzalez- Porras, 200929 幕 幕 † - 幕 幕 幕 幕幕幕幕幕 (5)
Heschl, 201838 幕 幕 幕 幕 幕 幕 幕 幕幕幕幕幕幕幕 (7)
Myers, 200440   幕   幕 幕幕 (2)
Pinilla- Gracia, 202033 幕 幕 幕   幕 幕幕幕幕 (4)
Pujol- Nicolas, 201731 幕 幕 † 幕幕 幕 幕 幕幕幕幕幕幕 (6)
Razurel, 201439 幕 幕   幕 幕 幕幕幕幕 (4)
Scardino, 201928 幕 幕 - 幕 幕 幕 幕幕幕幕幕 (5)
*Comparability assessed on the following: one star if matched or adjusted for degree of anaemia prior to iron treatment, another star awarded if adjusted or controlled for gender, type of 
surgery (THR or TKR) or comorbidities.
†No ascertainment of exposure for participants receiving oral iron, but IV iron exposure is recorded.
Ab, abstract; IV, intravenous; THR, total hip replacement; TKR, total knee replacement.
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estimated,37 data required conversion to the mean,31 
with a presenting Hb >130 g/L,29 or all of the above, had 
no discernible effect on the effect size estimate (online 
supplemental appendix 1).
Length of hospital stay
Five studies (n=1140 participants) report mean LoS but 
two do not report any measure of variance, or other statis-
tics that would allow this to be calculated.28 37 In line with 
Cochrane recommendations the mean of the SDs from 
the three other studies was used for these studies.26
The combined mean LoS in the no iron group was 8.72 
days (SD 4.97) and in the iron group was 6.12 days (SD 
4.19). LoS was reduced by an average of 2.08 days in the 
preoperative iron group compared with no iron (95% CI 
−2.64 to −1.51, p<0.001) (figure 6). Low heterogeneity 
(I2=40%) and no significant subgroup differences were 
observed (p=0.09).
All of the studies report the cause of anaemia as iron 
deficiency. When studies of low quality,39 with an esti-
mated SD,28 37 using a concurrent treatment,28 or with 
a presenting Hb >130 g/L28 were excluded a significant 
effect in favour of iron remains. When all exclusions are 
applied only two studies remain, reducing the power of 
pooled estimates.31 36 A beneficial effect of iron persists 
(MD −0.98 days), but the 95% CI is much wider (-2.02 to 
0.05 days, p=0.06, I2=0%, online supplemental appendix 
1F).
Change in Hb concentration
Six studies (n=325 participants) report average Hb concen-
trations pre- and post- iron treatment.29 33–36 41 Two studies 
Figure 2 Quality assessment of the included randomised controlled trial. IV, intravenous.
Table 4 De!nitions used with the Newcastle- Ottawa scale to assess quality of non- randomised studies of interventions in this 
review
Criteria Acceptable (star awarded) Unacceptable (star not awarded)
Representativeness of the 
exposed cohort
Truly or somewhat representative of the average 
anaemic patient awaiting elective THR/TKR. That 
is, consecutive series of participants pre and 
post—the time when iron treatment for anaemia was 
introduced.
Selected group of participants or no 
description.
Selection of the non- exposed 
cohort
Same setting as exposed cohort. Different setting from exposed cohort.
Ascertainment of exposure (to 
iron treatment)
Medical records of IV iron being given to patient or 
con!rmation oral iron taken by the patient.
Self- reported information or no 
information.
Comparability Controlled or adjusted for degree of anaemia before 
starting iron (ie, haemoglobin or haematocrit level) in 
analysis.
Did not control or adjust for degree of 
anaemia.
Controlled or adjusted for gender, comorbidities or 
type of surgery.
Did not control or adjust for any of these 
factors.
Assessment of outcome Independent blind assessment or linkage of 
electronic or paper clinical records.
Self- reported information or no 
information.
Adequacy of follow- up of 
cohorts
≥90% follow- up data for primary outcome, blood 
transfusion or adjustment for missing data.
<90% follow- up data for blood 
transfusion outcome and no adjustment 
for missing data.
IV, intravenous; THR, total hip replacement; TKR, total knee replacement.
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combined oral or intravenous iron as the intervention,29 36 
one used oral iron salts,41 one used intravenous iron only,33 
one compared two intravenous iron formulations34 and 
one used sucrosomial iron.35 The duration of treatment, 
and hence time between Hb measurements, was reported 
in five29 33 35 36 41 of the six studies. The average time was 28 
days. However, often this was not accurately reported, and 
where reported there was often a wide range of timings.
Iron was associated with a significant increase in 
mean Hb concentration (MD 11.48 g/L, 95% CI 8.12 to 
14.83 g/L,figure 7) .
In an exploratory analysis, a higher presenting Hb was 
associated with less of a Hb increase following iron treat-
ment (figure 8, slope of the regression line −0.30, 95% CI 
−0.59 to −0.19, p=0.04) and oral iron was associated with 
less of a Hb increase compared with intravenous iron 
(figure 9, slope of the regression line 7.50 g/L, 95% CI 
−2.24 to 17.24 g/L, p=0.11).
Hb concentrations after surgery were rarely reported, 
and where reported significant heterogeneity in timing 
was seen, therefore pooling studies in a meta- analysis 
was considered inappropriate. One study reported no 
difference36 with iron while two studies showed beneficial 
effects of preoperative iron on postoperative Hb.28 37
Figure 3 Funnel plot for primary outcome, perioperative 
blood transfusion rate. RR, risk ratio.
Figure 4 Forest plot comparing number of anaemic participants transfused in those receiving preoperative iron to no iron. IV, 
intravenous.
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Other outcomes
Three studies report some cost estimates, all favour iron. 
Savings estimates include $A400 000 per year (2012) for 
a 300 bed hospital with intravenous iron,36 €1763.25 
(2019) per patient with sucrosomial iron28 and £162.46 
(2017) per patient with a combined oral or intravenous 
iron approach.31
Other outcomes such as infection, medical complica-
tions and readmissions were rarely reported and, where 
they were, no differences were reported. Four studies 
(n=167 participants, 94 IV iron, 73 oral) report adverse 
events.33 34 36 41 Four participants (4%) in the intrave-
nous and three participants (4%) in the oral iron groups 
report minor complications. One study reported a signifi-
cantly reduced critical care admission rate favouring iron 
(control 4.9% vs intervention 0.5%, p=0.007).31 Another 
reports improved QoL outcomes with IV vs oral iron36 
using a modified short- form 36 questionnaire, however, 
there were concerns acknowledged by the study authors 
around these data and confounders.
Figure 5 Forest plot of units of blood transfused with outcome standardised to units per patient undergoing surgery. IV, 
intravenous.
Figure 6 Forest plot comparing the length of stay of in anaemic participants receiving preoperative iron or no iron. IV, 
intravenous.
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DISCUSSION
Preoperative anaemia is common in patients undergoing 
elective THR or TKR and is associated with poorer post-
operative outcomes and increased transfusion rates. 
This review has shown that the use of preoperative iron 
in anaemic participants is associated with a reduction 
in the number of participants requiring perioperative 
transfusion, the number of units transfused and LoS. 
The presenting Hb concentration and type of iron used 
appear to correlate with the degree of Hb increase, but 
insufficient data were available to examine correlation 
with postoperative outcomes.
However, the results should be interpreted with caution 
as only one of the included studies was an RCT at risk 
of bias. The analyses and meta- regression are, there-
fore, effectively observational and may exaggerate the 
true treatment effect. Higher quality evidence, such as a 
well conducted, adequately powered RCT is required to 
inform future clinical practice or policy change. A future 
RCT in this field could consider three treatment arms; no 
iron, oral iron and intravenous iron, and could include 
clinical, economic and QoL outcomes. Although, in the 
setting of existing guidelines, a no iron control group 
may prove difficult to implement and should be carefully 
considered.
Our results are in keeping with previous systematic 
reviews on preoperative anaemia optimisation in ortho-
paedic42–45 and other surgical populations.46–49 However, 
this is the first review to include NRSIs and focus solely 
on the use of preoperative iron in elective arthroplasty 
patients, as a means of patient optimisation before 
surgery. This group of patients have been described as 
one of the most appropriate for preoperative anaemia 
optimisation, due to the prevalence of iron deficiency 
anaemia and typical time available for anaemia optimisa-
tion on elective surgery pathways.8 Unlike other reviews, 
we have intentionally not included studies that include 
arthroplasty following trauma as the time available for 
preoperative optimisation with iron is minimal and this 
population is typically older, with more comorbidities and 
are more likely to encounter postoperative complications 
than elective arthroplasty patients.50
Figure 7 Forest plot of change in Hb pre- iron to post- iron accounting for correlation between result. FCM, Ferric 
Carboxymaltose; Hb, haemoglobin; IV, intravenous.
Figure 8 L'Abbe plot showing change in Hb from pre- iron 
to post- iron treatment by presenting Hb level. Each circle 
represents a group treated with one type of iron, some 
studies have two circles. Size relates to precision of estimate. 
Hb, haemoglobin.
Figure 9 L'Abbe plot showing change in Hb by oral or 
intravenous iron (excludes sucrosomial iron as only one study 
used this and reported pre- iron and post- iron Hb data). Hb, 
haemoglobin; IV, intravenous.
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Our results are also similar to those seen in meta- 
analyses on other PBM interventions such as the use of 
restrictive transfusion triggers, which have been estimated 
to reduce the risk of blood transfusion by 43% across a 
range of clinical specialties,51 and TXA, which has been 
estimated to reduce the risk of blood transfusion in 
surgical patients by 38%.52 However, it should be noted 
the quality of evidence for reduced transfusion triggers 
and TXA is much stronger as their estimated effect sizes 
are based on 31 and 129 randomised trials, respectively.
Treatment options
National and international guidelines recommend that 
treatment for preoperative anaemia is directed by the 
underlying cause.10 12 For the majority of patients under-
going elective THR or TKR this is likely to be iron defi-
ciency (functional of absolute) which would be expected 
to respond to iron.2 33 However, this will not always be 
the cause. Algorithms for diagnosis and management 
of perioperative anaemia have been proposed, but the 
effectiveness of these is beyond the scope of this review.12 
Three studies in this review appeared to give iron without 
assessing the underlying cause of anaemia. All three 
showed a beneficial effect of iron, possibly because iron 
was used in the setting of iron deficiency, but this was not 
clearly reported, or because only a minority of patients 
had anaemia of another cause.
Three studies in this review used a predefined decision- 
making algorithm to determine preoperative anaemia 
treatment.29 31 38 This approach seems logical given 
there may be a different underlying cause of preopera-
tive anaemia, differing tolerance to oral iron and varia-
tions in timing of screening in relation to surgery. This 
approach is also in keeping with international guidance.12 
One study included a ‘safety- net’ of referral for further 
investigation if the Hb and/or ferritin levels were consid-
ered too low,31 in keeping with guidance from the British 
Society of Gastroenterology.53
As identified in this review there are different iron 
treatments available including oral iron salts, oral sucro-
somial iron and intravenous iron preparations. While 
this review lacks high quality RCTs, which might allow 
us to recommend an optimum treatment modality, our 
exploratory analysis suggests intravenous iron correlates 
with a greater Hb increase than oral iron. However, no 
significant subgroup differences between iron prepara-
tions were seen for postoperative outcomes, although 
this analysis may have been underpowered and was not a 
randomised comparison between modes of delivery.
Debate continues around the optimal dose and admin-
istration technique for oral iron salts, to maximise absorp-
tion and reduce side effects. Recent recommendations 
involve lower daily or alternate day doses (40–100 mg 
elemental iron) along with specific administration 
advice54; newer phospholipid bound sucrosomial iron 
formulations offer a potential oral alternative. High- 
quality RCTs comparing the effectiveness of different 
dosing regimens, or testing newer oral iron preparations 
are required to direct future clinical practice.55
Concerns around the safety of intravenous iron exist 
based largely on the risks of anaphylaxis seen with older 
preparations. A network meta- analysis found them to 
be safe and effective at increasing Hb concentrations in 
anaemic and non- anaemic iron deficient participants, 
across a range of medical specialties.56 However, even with 
newer intravenous iron preparations further work may 
be needed to identify the optimum formulation. Bisbe 
et al
34 compared intravenous iron sucrose with intrave-
nous ferric carboxymaltose, and found they produced a 
comparable Hb response, but participants receiving intra-
venous ferric carboxymaltose required fewer treatment 
sessions to receive their total iron dose (mean 4 sessions 
vs 2 sessions, p<0.001). This is likely to be attractive to 
patients, clinicians and policy- makers, so an intravenous 
iron preparation that allows a total dose infusion may 
warrant further investigation.
Timing
There was considerable variability in the timing of 
commencing iron treatment before surgery. A recent 
international consensus statement on the management of 
perioperative anaemia and iron- deficiency recommends 
oral iron be given for 6–8 weeks prior to surgery and IV 
iron used if surgery is planned within 6 weeks.12 However, 
work by Muñoz et al found that even very short- term 
perioperative intravenous iron, given either 2–5 days 
preoperatively and/or 2–3 days postoperatively, signifi-
cantly reduced transfusion rates and length of stay.57 
Where oral iron was used in the studies included in this 
review it was typically for less than the 6–8 weeks recom-
mended, which may be limiting the beneficial effects of 
oral iron seen.
De!nition of anaemia
Two studies included participants with a presenting Hb 
greater than 130 g/L (tables 1 and 2)28 29 reported a bene-
ficial effect of iron on postoperative outcomes (number 
of participants and units transfused and LoS). This may 
support the opinion that gender- specific definitions of 
preoperative anaemia are not appropriate, and might 
even suggest Hb thresholds of 130 g/L are too low.12 13 20
Strengths and limitations
Our review methodology followed a preregistered 
protocol and is reported in line with Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses guid-
ance.26 58 However, as with any meta- analysis, this review 
is limited by the included studies and despite our 
efforts it is possible some studies may have been missed. 
Comprehensive searching techniques were used and 
NRSI designs with a control group were included. Hand-
searching identified four additional studies, not found 
in the database searches.29 34 36 37 This initially raised 
concerns and prompted a review of the search strategy, 
but no major issues were identified. When looking closer 
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at the source of these four studies it became clear that 
the database searches would not have been expected to 
identify them. Our comprehensive searches identified 
two non- English language studies. Despite our extensive 
searches, which included the grey literature to reduce 
the risk of publication bias, a funnel plot suggests there 
may be evidence of publication bias, though there were 
only ten studies and other explanations cannot be 
excluded.
Observational study designs and studies with low 
event rates, as seen in most studies in this review, are at 
higher risk of bias and may exaggerate treatment effects 
compared with well conducted, adequately powered 
RCTs.59 60 Although measures have been taken to explore 
the impact of low quality studies in our sensitivity anal-
ysis, the sparse data seen in many of the included studies, 
and the lack of any high quality RCTs in this review does 
limit the reliability of our results and the conclusions that 
can be drawn from them.60 Ideally RCTs and NRSIs would 
have been pooled separately due to differential risk of 
bias; however, given there was only a single small RCT we 
pooled this with the NRSIs.
Differences in how data on the quantity of blood trans-
fused are reported, meant calculations to standardise 
these were required. Further work to define a standard 
definition for reporting, which would aid interpretation 
and data pooling, may be warranted.
Few studies measured patient adherence for those 
assigned to receive oral iron. It is well documented that 
adherence to oral iron salts can be an issue.61 There was 
also considerable variation in the timing and duration of 
treatments even within studies, with one giving oral iron 
for between 6 and 151 days. Given it would be expected to 
take 2–4 weeks to see a Hb response to oral iron, 6 days is 
almost certainly too short for any meaningful effect to take 
place.62 Both of these limitations may underestimate the 
true treatment effects of iron, yet despite this, significant 
clinical benefits are seen in this meta- analysis. In several 
studies there was little adjustment for confounders which 
may impact on a patient’s risk of receiving a blood trans-
fusion notably presenting Hb concentration or cardiore-
spiratory comorbidities, which were often used to trigger 
blood transfusion. In addition, the use of other PBM 
interventions in routine use was poorly reported across 
the included studies, with most not reporting on these 
at all. Where they were, this was typically not quantified 
and only referred to as being in ‘routine practice’. These 
potential confounders were therefore typically not well 
controlled or adjusted for across studies. This review also 
included studies where a treatment in addition to iron 
was given for up to 20% of participants, this was designed 
to be pragmatic but may have amplified the results in rela-
tion to the true effectiveness of iron. However, only two 
participants received concurrent EPO, and this study was 
excluded during sensitivity analysis. In addition, observed 
improvements in LoS should be considered on a back-
ground of general reductions in LoS for elective THR or 
TKR over time.63 64
CONCLUSION
Based on the best available evidence, preoperative 
anaemia management with iron in participants under-
going elective THR or TKR significantly reduces the 
number of participants requiring RBC transfusion, the 
number of units transfused and LoS. However, these 
results should be interpreted with a caution as high- 
quality evidence is lacking.
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